MPOX
Category: Press release
Transgene’s Combined General Meeting of May 22, 2026
AG 2026
Availability of Preparatory Documents for the Combined General Meeting of May 22, 2026
AG 2026
Transgene Provides Business and Financial Update for Q1 2026
Q1 2026
Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head and Neck Cancer
TG4050
Transgene to Participate in Upcoming Investor Meetings
Investor meetings
Transgene and NEC Bio Sign License Agreement to Prepare the Next Steps of the Development of TG4050 in Head and Neck Cancer
Licence Agreement
Transgene to Deliver an Oral Presentation on its Individualized Neoantigen Therapeutic Vaccine TG4050 at the World Vaccine Congress
WVC 2026
Transgene Continues Progress to Reshape Early-Stage Cancer Treatment through Individualized Neoantigen Therapeutic Vaccines (INTV) Backed by Financial Visibility Until Early 2028
Business FYR 2025
Transgene Announces Financial Calendar for 2026
financial calendar 2026